It has been reported that inhibition of GSK-3β by different compounds, including TDZD-8, causes an inactivation of NF-κB activity [31], [32] and Kotliarova et al have shown that several small molecular inhibitors of GSK-3β activity inhibit glioma cell survival in part through a decrease in intracellular NF-κB activity [30]. Here, NFKB1 is linked to central nervous system cancer.